Free Trial

Contract Signed For 1.8bn More Pfizer/BioNTech Vaccine Doses

EU COMMISSION

European Commission tweets: "Today we signed a third contract with BioNTech-Pfizer for an additional 1.8 billion doses between end 2021 and 2023. This is good news for our long-term fight to protect European citizens against the virus and its variants."

  • Link to statement: https://ec.europa.eu/commission/presscorner/detail...
  • Since the rancour that surrounded the reduced delivery of AstraZeneca doses in February this year and the subsequent, largely unfounded, fears surrounding blood clots the EU has put significant focus on securing more Pfizer/BioNTech doses.
  • The prime reason behind this is that it is largely produced within the EU, and as such member states would not be reliant on shipment of doses from outside the bloc.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.